Linked Life Data

16109591

Source:http://linkedlifedata.com/resource/pubmed/id/16109591

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2005-8-19
pubmed:abstractText
In a single-blinded and randomized pilot study efficacy and tolerability of oxcarbazepine versus carbamazepine were investigated in 29 patients during therapy of alcohol withdrawal. No initial differences were found regarding sociodemographic data and alcohol-related parameters, indicating successful randomization. The oxcarbazepine group showed a significant decrease of withdrawal symptoms and reported significantly less 'craving for alcohol' compared to the carbamazepine group. Subjectively experienced side effects, normalization of vegetative parameters and improvement in the cognitive processing speed did not reveal differences for both groups. Therefore, oxcarbazepine might be an interesting alternative to carbamazepine, and having almost no addictive potential, no clinically relevant interaction with alcohol and no prominent sedatory effect, possibly also to other drugs such as benzodiazepines or clomethiazole, in the treatment of alcohol withdrawal syndrome.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1355-6215
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
283-8
pubmed:dateRevised
2007-3-27
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Oxcarbazepine versus carbamazepine in the treatment of alcohol withdrawal.
pubmed:affiliation
Department of Clinical Psychiatry and Psychotherapy, Hannover Medical School, Germany. schik.gesa@mh-hannover.de
pubmed:publicationType
Journal Article, Randomized Controlled Trial